A single 99mTc-MIBI study to predict response to neoadjuvant treatment in sarcoma patiens

Hellenic Journal of Nuclear Medicine

Volumn 14, Issue 2, 2011, Pages

  Sohaib, Muhammad ^a   Wiqar, Muhammad Amin ^b   Ali, Mujahid Khalid ^b   Hussain, Fida ^b   Umer i Farooq, ^b  

^a PAKISTAN INSTITUTE OF ENGINEERING AND APPLIED SCIENCES   (Pakistan)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (Pakistan)

Author keywords

Necrosis; Neoadjuvant treatment; Sarcoma; Technetium 99mTc sestamibi

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TECHNETIUM 99M;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; MALE; OSTEOSARCOMA; SCHOOL CHILD; SOFT TISSUE SARCOMA; TUMOR NECROSIS; TUMOR SCINTISCANNING;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; NECROSIS; NEOADJUVANT THERAPY; OSTEOSARCOMA; PROGNOSIS; RADIOPHARMACEUTICALS; SARCOMA; SOFT TISSUE NEOPLASMS; TECHNETIUM TC 99M SESTAMIBI; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79961135654     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Bacci G, Ferrari S, Mercuri M et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years. Acta Orthop 2007; 78: 377-84.
2. Spira AI, Ettinger DS. The Use of Chemotherapy in soft-tissue sarcomas. Oncologist 2002; 7: 348-59.
3. Bielack SS, Kempf-Bielack B, Delling G et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-90. (Pubitemid 34111386)
4. Picci P, Bacci G, Campanacci M et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 1985; 56: 1515-21. (Pubitemid 15228493)
5. Fletcher BD. Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation. Am J Roentgenol 1991; 157: 825-33.
6. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
7. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. J Nucl Med 2009; 50: 122S-50S.
8. 99mTc-hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs. Clin Nucl Med 1989; 14: 333-40. (Pubitemid 19145458)
9. Gottesman MM. Mechanisms of cancer drug resistance. Ann Rev Med 2002; 53: 615-27. (Pubitemid 34177898)
10. 99mTc-MIBI Scan in Patients with Multiple Myeloma. Cancer Biother Radiopharm 2004; 19: 165-70. (Pubitemid 38685114)
11. 99mTc- sestamibi in predicting response to chemotherapy in patients with multiple myeloma, Q J Nucl Med Mol Imaging 2005; 49: 281-5. (Pubitemid 41569516)
12. 99mTc-MIBI uptake. Nucl Med Commun 2002; 23: 31-8. (Pubitemid 34214304)
13. 99mTc-MIBI SPECT imaging in patients with lung carcinoma: is it a functional probe of multidrug resistance genes? J Comput Assist Tomogr 2007; 31: 795-9. (Pubitemid 47482503)
14. 99mTc-MIBI in the assessment of response to chemotherapy and detection of recurrences in bone and soft tissue tumours of the extremities. Q J Nucl Med 2003; 47: 51-7. (Pubitemid 36826762)
15. 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response. Eur J Nucl Med 2001; 28: 1341-50.
16. Hicks RJ, Toner GC, Choong PFM. Clinical applications of molecular imaging in sarcoma evaluation. Cancer Imaging 2005; 5; 66-72.
17. McCarvill MB, Christie R, Daw NC et al. PET/CT in the evaluation of childhood sarcomas. Am J Roentgenol 2005; 184: 1393-404.
18. 99mTc-MIBI scintigraphy in musculoskeletal tumors. J Nucl Med 2001; 42: 33-7.
19. 99mTechnetium-methoxyisobutyl-isonitrile with histological necrosis following induction chemotherapy or measures of P-glycoprotein expression in high-grade osteosarcoma. Clin Cancer Research 2001; 7: 3065-70. (Pubitemid 32963825)
20. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression. J Nucl Med 2003; 44: 1394-401. (Pubitemid 39663350)
21. 201TI scintigraphy and angiography. Int J Clin Oncol [serial online] 2011 Feb [cited 2011 May 17); 16: [20 screens] Available from URL: http://dx.doi.org/10.1007/s10147-011-0194-6.
22. Bacci G, Briccoli A, Rocca M et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 2003; 14: 1126-34. (Pubitemid 36950179)
23. Pezzi CM, Pollock RE, Evans HL et al. Preoperative chemotherapy for soft tissue sarcoma of the extremities. Ann Surg 1990; 211: 476-81.
24. Casper ES, Gaynor JJ, Harrison LB et al. Preoperative and post-operative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma. Cancer 1994; 73: 1644-51. (Pubitemid 24085264)
25. Wilkins RM, Cullen JW, Odom L et al. Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol 2003; 10: 498-507. (Pubitemid 40486912)